POM-V Prescription Required Companion Animal

Catzol 10 mg/ml Oral Solution for Cats

Active ingredient: Itraconazole

Form

Liquid

Species

Cats

Manufacturer

Vetpharma Animal Health, S.L

VMD MA No.

32509/4033

What it's used for

Treatment of dermatophytosis caused by Microsporum canis.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Itraconazole

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Catzol 10 mg/ml Oral Solution for Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 18 Mar 2026.

Treatment of dermatophytosis caused by Microsporum canis.

For oral use.
Administer 5mg of itraconazole per kg body weight once daily, equivalent to 0.5 mL
of the product per kg body weight once daily. The solution should be administered
directly into the mouth by means of a dosing syringe.
The dosage regime is 0.5 ml/kg/day for 3 alternate periods of 7 consecutive days,
each time with 7 days without treatment in between.
days
days
days
days
days
t
reatment
n
o treatment
t
reatment
n
o treatment
t
reatment
The dosing syringe shows graduations per 200 gram of body weight. Fill the syringe
by pulling the plunger until it reaches the graduation corresponding to the correct
body weight of the cat.
When administering the product to kittens, the administrator should be careful not to
administer more than the recommended dose/weight. For kittens weighing less than
0.5 kg, a 1 ml syringe which allows proper dosing should be used.

Revised: October 2024
AN: 00808/2024 & 01286/2024
Treat the animal by slowly and gently injecting the liquid into the mouth, allowing the
cat to swallow the product.
After dosing, the syringe should be removed from the bottle, washed and dried and
the cap should be screwed back on tightly.
Data in humans shows that food intake may result in lower drug absorption.
Therefore, it is recommended to administer the product by preference between
meals.
In some cases, a prolonged time between clinical and mycological cure may be
observed. In cases where a positive culture is obtained 4 weeks after the end of
administration, the treatment should be repeated once at the same dosage regimen
and the underlying disease addressed.

Do not use in cases of hypersensitivity to itraconazole, to other azoles or to any of
the excipients.
Do not use in cases of impaired liver or kidney function.
Do not use in pregnant and lactating queens (see section 4.7).

Some form of adverse reaction possibly related to the administration of the product
were noted in clinical studies. Common adverse reactions were vomiting, diarrhoea,
anorexia, salivation, depression and apathy. These effects are usually mild and
transient. In very rare cases a transient increase in liver enzymes may occur. In very
rare cases this was associated with icterus. If clinical signs suggestive of liver
dysfunction develop, treatment should be discontinued immediately.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s)).
- common (more than 1 but less than 10 animals in 100 animals treated).
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated).
- rare (more than 1 but less than 10 animals in 10,000 animals treated).
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Some cases of feline dermatophytosis can be difficult to cure, especially in catteries.
Cats treated with itraconazole can still infect other cats with M. canis as long as they
are not mycologically cured. It is therefore advised to minimise the risk of re-infection

Revised: October 2024
AN: 00808/2024 & 01286/2024
or spread of infection by keeping healthy animals (including dogs as they can also be
infected by M. canis) separate from cats that are being treated. Cleaning and
disinfection of the environment with appropriate fungicidal products is highly
recommended – especially in case of group problems.
When clipping the hair of infected cats, the advice of the veterinarian should be
sought first.
Clipping of the hair coat is considered useful because it removes infected hairs,
stimulates new hair growth and hastens recovery. It is strongly recommended that
clipping is performed by a veterinarian. In cases with limited lesions, hair clipping can
be limited to the lesions only, whereas in cats with generalized dermatophytosis it is
recommended to clip the entire hair coat. Care should be taken not to cause trauma
to the underlying skin during clipping. It is recommended that disposable, protective
clothing and gloves are worn during the clipping of the affected animals. The clipping
of the hair should be performed in a well-ventilated room which can be disinfected
after clipping. The hairs should be disposed of appropriately and all instruments,
clippers etc. should be disinfected.
Treatment of dermatophytosis should not be limited to treatment of the infected
animal(s). It should also include disinfection of the environment with appropriate
fungicidal products, since
months. Other measures such as frequent vacuuming, disinfection of grooming
equipment and removal of all potentially contaminated material that cannot be
disinfected will minimize the risk of re-infection or spread of infection. Disinfection and
vacuuming should be limited to surfaces which may not be cleaned with a damp
cloth. All other surfaces should be cleaned with a damp cloth. Any cloth used for
cleaning should be washed and disinfected or disposed of and the used vacuum
cleaner bag should be disposed of.

Measures to prevent introduction of M. canis into groups of cats may include isolation
of new cats, isolation of cats returning from shows or breeding, exclusion of visitors
and periodic monitoring by Wood's lamp or by culturing for M. canis.
In refractory cases the possibility of an underlying disease should be considered.

Frequent and repeated use of an antimycotic may result in the induction of resistance
to antimycotics of the same class

Special precautions for use in animals
Cats suffering from dermatophytosis, but also in poor general condition and/or
suffering from additional diseases or impaired immunological response should be
monitored closely during treatment. Because of their condition, this category of
animals may be more sensitive to the development of adverse effects. In case of a
serious adverse effect, treatment should be interrupted and supportive care therapy
(fluid therapy) should be initiated if necessary. If clinical signs suggestive of liver
dysfunction develop, treatment should be discontinued immediately. It is very
important to monitor liver enzymes in animals showing signs of liver dysfunction.

Revised: October 2024
AN: 00808/2024 & 01286/2024
In humans, itraconazole has been associated with heart failure due to a negative
inotropic effect. Cats suffering from heart diseases should be carefully monitored and
the treatment should be withdrawn if the clinical signs deteriorate.
Disinfection and vacuuming should be continued for an extended period after the cat
is clinically cured, but vacuuming should be limited to surfaces which may not be
cleaned with a damp cloth.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
If a suspected lesion occurs on a human, consult a physician, since
dermatophytosis is a zoonotic disease. Therefore, wear latex gloves when clipping
hair of infected cats, when handling the animal during treatment or when cleaning the
syringe.
This veterinary medicinal product may cause skin and/or eye irritation. Avoid contact
with skin and eyes. Wash hands and exposed skin after use. In case of accidental
contact with eyes, rinse thoroughly with water. In case of persistent pain or irritation,
seek medical advice and show the label or package leaflet to the physician.
This product may be harmful after accidental ingestion by children. Do not leave the
filled syringe unattended. In case of accidental ingestion, rinse mouth with water.
This product may cause hypersensitivity reactions. People with known
hypersensitivity to itraconazole or propylene glycol should avoid contact with the
veterinary medicinal product. Wash hands after use.

Vomiting, hepatic and renal disorders were seen after concomitant treatment of the
veterinary medicinal product and cefovecin. Symptoms like motor incoordination,
faecal retention and dehydration are observed when tolfenamic acid and the
veterinary medicinal product are given simultaneously. Co-administration of the
product and these drugs, in absence of data in cats, should be avoided.
In human medicine, interactions between itraconazole and certain other drugs have
been described, resulting from interactions with cytochrome P450 3A4 (CYP3A4) and
P-glycoproteins (PgP). This may result in increased plasma concentrations of e.g.
oral midazolam, cyclosporin, digoxin, chloramphenicol, ivermectin, or
methylprednisolone. The increased plasma levels can prolong the duration of effects
as well as side effects. Itraconazole may also increase the serum level of oral
antidiabetic agents, which may result in hypoglycaemia.
On the other hand, some drugs, e.g. barbiturates or phenytoin can increase the rate
of metabolism of itraconazole, resulting in a decreased bioavailability, hence a
decreased efficacy. As itraconazole requires an acidic environment for maximal
absorption, antacids cause a marked reduction in absorption. Concomitant use of
erythromycin can increase the plasma concentration of itraconazole.
Interactions in humans between itraconazole and calcium antagonists have also
been reported. These drugs might have additive negative inotropic effects to the
heart.
It is not known to what extent these interactions are relevant for cats, but in the
absence of data, co-administration of the product and these drugs should be
avoided.

For the full list of excipients, see section

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.